APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Tyrosine Kinase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Non-Tyrosine Kinase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025195 pages

Choose your research edition.

Industry ResearchNon-Tyrosine Kinase Inhibitors Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Tyrosine Kinase Inhibitors Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Non-Tyrosine Kinase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Tyrosine Kinase Inhibitors Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Tyrosine Kinase Inhibitors Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Non-Tyrosine Kinase Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Non-Tyrosine Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-Tyrosine Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-Tyrosine Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Non-Tyrosine Kinase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Non-Tyrosine Kinase Inhibitors include Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GlaxoSmithKline (GSK), Onconova Therapeutics, Nerviano Medical Sciences and Jasco Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Non-Tyrosine Kinase Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-Tyrosine Kinase Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-Tyrosine Kinase Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-Tyrosine Kinase Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Non-Tyrosine Kinase Inhibitors Segment by Company

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

GlaxoSmithKline (GSK)

Onconova Therapeutics

Nerviano Medical Sciences

Jasco Pharmaceuticals

Eternity Bioscience

Daiichi Sankyo

Cyclacel Pharmaceuticals

Celgene Corporation

Carna Biosciences

AstraZeneca

Astex Pharmaceuticals

Array BioPharma

Non-Tyrosine Kinase Inhibitors Segment by Type

CDK Inhibitors

mTOR Inhibitors

RAF/MEK Inhibitors

Non-Tyrosine Kinase Inhibitors Segment by Application

Brain Cancer

Respiratory Cancer

Liver Cancer

Others

Non-Tyrosine Kinase Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Tyrosine Kinase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Tyrosine Kinase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Tyrosine Kinase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Non-Tyrosine Kinase Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Non-Tyrosine Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Non-Tyrosine Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Non-Tyrosine Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Non-Tyrosine Kinase Inhibitors Industry Trends Table 2. Non-Tyrosine Kinase Inhibitors Industry Drivers Table 3. Non-Tyrosine Kinase Inhibitors Industry Opportunities and Challenges Table 4. Non-Tyrosine Kinase Inhibitors Industry Restraints Table 5. Global Non-Tyrosine Kinase Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Non-Tyrosine Kinase Inhibitors Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Manufacturers Table 9. Global Non-Tyrosine Kinase Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Non-Tyrosine Kinase Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Non-Tyrosine Kinase Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Non-Tyrosine Kinase Inhibitors Manufacturers, Product Type & Application Table 13. Global Non-Tyrosine Kinase Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Non-Tyrosine Kinase Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CDK Inhibitors Table 17. Major Manufacturers of mTOR Inhibitors Table 18. Major Manufacturers of RAF/MEK Inhibitors Table 19. Global Non-Tyrosine Kinase Inhibitors Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2026) & (W Units) Table 21. Global Non-Tyrosine Kinase Inhibitors Sales by Type (2027-2032) & (W Units) Table 22. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2021-2026) Table 23. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2027-2032) Table 24. Global Non-Tyrosine Kinase Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Non-Tyrosine Kinase Inhibitors Revenue by Type (2021-2026) & (W Units) Table 26. Global Non-Tyrosine Kinase Inhibitors Revenue by Type (2027-2032) & (W Units) Table 27. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Type (2021-2026) Table 28. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Brain Cancer Table 30. Major Manufacturers of Respiratory Cancer Table 31. Major Manufacturers of Liver Cancer Table 32. Major Manufacturers of Others Table 33. Global Non-Tyrosine Kinase Inhibitors Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2026) & (W Units) Table 35. Global Non-Tyrosine Kinase Inhibitors Sales by Application (2027-2032) & (W Units) Table 36. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2021-2026) Table 37. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2027-2032) Table 38. Global Non-Tyrosine Kinase Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Non-Tyrosine Kinase Inhibitors Revenue by Application (2021-2026) & (W Units) Table 40. Global Non-Tyrosine Kinase Inhibitors Revenue by Application (2027-2032) & (W Units) Table 41. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Application (2021-2026) Table 42. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Application (2027-2032) Table 43. Global Non-Tyrosine Kinase Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Non-Tyrosine Kinase Inhibitors Sales by Region (2021-2026) & (W Units) Table 45. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global Non-Tyrosine Kinase Inhibitors Sales Forecasted by Region (2027-2032) & (W Units) Table 47. Global Non-Tyrosine Kinase Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 49. North America Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 50. North America Non-Tyrosine Kinase Inhibitors Sales by Country (2027-2032) & (W Units) Table 51. Europe Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 53. Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2027-2032) & (W Units) Table 54. Asia Pacific Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Asia Pacific Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 56. Asia Pacific Non-Tyrosine Kinase Inhibitors Sales by Country (2027-2032) & (W Units) Table 57. South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2026) & (W Units) Table 59. South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2027-2032) & (W Units) Table 60. Global Non-Tyrosine Kinase Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Non-Tyrosine Kinase Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Non-Tyrosine Kinase Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Region (2021-2026) Table 64. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Region (2027-2032) Table 65. Novartis Company Information Table 66. Novartis Business Overview Table 67. Novartis Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Novartis Non-Tyrosine Kinase Inhibitors Product Portfolio Table 69. Novartis Recent Development Table 70. Merck KGaA Company Information Table 71. Merck KGaA Business Overview Table 72. Merck KGaA Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck KGaA Non-Tyrosine Kinase Inhibitors Product Portfolio Table 74. Merck KGaA Recent Development Table 75. Roche Company Information Table 76. Roche Business Overview Table 77. Roche Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Roche Non-Tyrosine Kinase Inhibitors Product Portfolio Table 79. Roche Recent Development Table 80. Eli Lilly Company Information Table 81. Eli Lilly Business Overview Table 82. Eli Lilly Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Eli Lilly Non-Tyrosine Kinase Inhibitors Product Portfolio Table 84. Eli Lilly Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Pfizer Non-Tyrosine Kinase Inhibitors Product Portfolio Table 89. Pfizer Recent Development Table 90. GlaxoSmithKline (GSK) Company Information Table 91. GlaxoSmithKline (GSK) Business Overview Table 92. GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Portfolio Table 94. GlaxoSmithKline (GSK) Recent Development Table 95. Onconova Therapeutics Company Information Table 96. Onconova Therapeutics Business Overview Table 97. Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Portfolio Table 99. Onconova Therapeutics Recent Development Table 100. Nerviano Medical Sciences Company Information Table 101. Nerviano Medical Sciences Business Overview Table 102. Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Portfolio Table 104. Nerviano Medical Sciences Recent Development Table 105. Jasco Pharmaceuticals Company Information Table 106. Jasco Pharmaceuticals Business Overview Table 107. Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio Table 109. Jasco Pharmaceuticals Recent Development Table 110. Eternity Bioscience Company Information Table 111. Eternity Bioscience Business Overview Table 112. Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Portfolio Table 114. Eternity Bioscience Recent Development Table 115. Daiichi Sankyo Company Information Table 116. Daiichi Sankyo Business Overview Table 117. Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Portfolio Table 119. Daiichi Sankyo Recent Development Table 120. Cyclacel Pharmaceuticals Company Information Table 121. Cyclacel Pharmaceuticals Business Overview Table 122. Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio Table 124. Cyclacel Pharmaceuticals Recent Development Table 125. Celgene Corporation Company Information Table 126. Celgene Corporation Business Overview Table 127. Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Portfolio Table 129. Celgene Corporation Recent Development Table 130. Carna Biosciences Company Information Table 131. Carna Biosciences Business Overview Table 132. Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Portfolio Table 134. Carna Biosciences Recent Development Table 135. AstraZeneca Company Information Table 136. AstraZeneca Business Overview Table 137. AstraZeneca Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. AstraZeneca Non-Tyrosine Kinase Inhibitors Product Portfolio Table 139. AstraZeneca Recent Development Table 140. Astex Pharmaceuticals Company Information Table 141. Astex Pharmaceuticals Business Overview Table 142. Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio Table 144. Astex Pharmaceuticals Recent Development Table 145. Array BioPharma Company Information Table 146. Array BioPharma Business Overview Table 147. Array BioPharma Non-Tyrosine Kinase Inhibitors Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Array BioPharma Non-Tyrosine Kinase Inhibitors Product Portfolio Table 149. Array BioPharma Recent Development Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Non-Tyrosine Kinase Inhibitors Distributors List Table 153. Non-Tyrosine Kinase Inhibitors Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Non-Tyrosine Kinase Inhibitors Product Image Figure 2. Global Non-Tyrosine Kinase Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Tyrosine Kinase Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-Tyrosine Kinase Inhibitors Sales (2021-2032) & (W Units) Figure 5. Global Non-Tyrosine Kinase Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Non-Tyrosine Kinase Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CDK Inhibitors Image Figure 9. mTOR Inhibitors Image Figure 10. RAF/MEK Inhibitors Image Figure 11. Global Non-Tyrosine Kinase Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Non-Tyrosine Kinase Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2021-2032) Figure 14. Global Non-Tyrosine Kinase Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Type (2021-2032) Figure 17. Brain Cancer Image Figure 18. Respiratory Cancer Image Figure 19. Liver Cancer Image Figure 20. Others Image Figure 21. Global Non-Tyrosine Kinase Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Non-Tyrosine Kinase Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2021-2032) Figure 24. Global Non-Tyrosine Kinase Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 28. North America Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 29. U.S. Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Canada Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Mexico Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Europe Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Germany Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 35. France Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 36. U.K. Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Italy Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Netherlands Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Asia Pacific Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 41. China Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Japan Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 43. South Korea Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Southeast Asia Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 45. India Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Australia Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Market Share by Country (2021-2032) Figure 49. Brazil Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South Africa Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Saudi Arabia Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Turkey Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Argentina Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 54. UAE Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Egypt Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Chile Non-Tyrosine Kinase Inhibitors Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Global Non-Tyrosine Kinase Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Non-Tyrosine Kinase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. North America Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Non-Tyrosine Kinase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Europe Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Non-Tyrosine Kinase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Non-Tyrosine Kinase Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Non-Tyrosine Kinase Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • CDK Inhibitors
  • mTOR Inhibitors
  • RAF/MEK Inhibitors
Applications
  • Brain Cancer
  • Respiratory Cancer
  • Liver Cancer
  • Others
Companies covered
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline (GSK)
  • Onconova Therapeutics
  • Nerviano Medical Sciences
  • Jasco Pharmaceuticals
  • Eternity Bioscience
  • Daiichi Sankyo
  • Cyclacel Pharmaceuticals
  • Celgene Corporation
  • Carna Biosciences
  • AstraZeneca
  • Astex Pharmaceuticals
  • Array BioPharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Non-Tyrosine Kinase Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Non-Tyrosine Kinase Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Non-Tyrosine Kinase Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Non-Tyrosine Kinase Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Non-Tyrosine Kinase Inhibitors Market Dynamics
  1. 2.1 Non-Tyrosine Kinase Inhibitors Industry Trends
  2. 2.2 Non-Tyrosine Kinase Inhibitors Industry Drivers
  3. 2.3 Non-Tyrosine Kinase Inhibitors Industry Opportunities and Challenges
  4. 2.4 Non-Tyrosine Kinase Inhibitors Industry Restraints
3 Non-Tyrosine Kinase Inhibitors Market by Manufacturers
  1. 3.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Non-Tyrosine Kinase Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Non-Tyrosine Kinase Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Non-Tyrosine Kinase Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Non-Tyrosine Kinase Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Non-Tyrosine Kinase Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Non-Tyrosine Kinase Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Non-Tyrosine Kinase Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Non-Tyrosine Kinase Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Non-Tyrosine Kinase Inhibitors Tier 1, Tier 2, and Tier 3
4 Non-Tyrosine Kinase Inhibitors Market by Type
  1. 4.1 Non-Tyrosine Kinase Inhibitors Type Introduction
  2. 4.1.1 CDK Inhibitors
  3. 4.1.2 mTOR Inhibitors
  4. 4.1.3 RAF/MEK Inhibitors
  5. 4.2 Global Non-Tyrosine Kinase Inhibitors Sales by Type
  6. 4.2.1 Global Non-Tyrosine Kinase Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Non-Tyrosine Kinase Inhibitors Sales by Type (2021-2032)
  8. 4.2.3 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2021-2032)
  9. 4.3 Global Non-Tyrosine Kinase Inhibitors Revenue by Type
  10. 4.3.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Non-Tyrosine Kinase Inhibitors Revenue by Type (2021-2032)
  12. 4.3.3 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Type (2021-2032)
5 Non-Tyrosine Kinase Inhibitors Market by Application
  1. 5.1 Non-Tyrosine Kinase Inhibitors Application Introduction
  2. 5.1.1 Brain Cancer
  3. 5.1.2 Respiratory Cancer
  4. 5.1.3 Liver Cancer
  5. 5.1.4 Others
  6. 5.2 Global Non-Tyrosine Kinase Inhibitors Sales by Application
  7. 5.2.1 Global Non-Tyrosine Kinase Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Non-Tyrosine Kinase Inhibitors Sales by Application (2021-2032)
  9. 5.2.3 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Application (2021-2032)
  10. 5.3 Global Non-Tyrosine Kinase Inhibitors Revenue by Application
  11. 5.3.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Non-Tyrosine Kinase Inhibitors Revenue by Application (2021-2032)
  13. 5.3.3 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Non-Tyrosine Kinase Inhibitors Sales by Region
  1. 6.1 Global Non-Tyrosine Kinase Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-Tyrosine Kinase Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Non-Tyrosine Kinase Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Non-Tyrosine Kinase Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Non-Tyrosine Kinase Inhibitors Revenue by Region
  1. 7.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Region
  2. 7.1.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Non-Tyrosine Kinase Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Non-Tyrosine Kinase Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Non-Tyrosine Kinase Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Non-Tyrosine Kinase Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Non-Tyrosine Kinase Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Non-Tyrosine Kinase Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Non-Tyrosine Kinase Inhibitors Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck KGaA
  8. 8.2.1 Merck KGaA Company Information
  9. 8.2.2 Merck KGaA Business Overview
  10. 8.2.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck KGaA Non-Tyrosine Kinase Inhibitors Product Portfolio
  12. 8.2.5 Merck KGaA Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Non-Tyrosine Kinase Inhibitors Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Non-Tyrosine Kinase Inhibitors Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Non-Tyrosine Kinase Inhibitors Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline (GSK)
  32. 8.6.1 GlaxoSmithKline (GSK) Company Information
  33. 8.6.2 GlaxoSmithKline (GSK) Business Overview
  34. 8.6.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Portfolio
  36. 8.6.5 GlaxoSmithKline (GSK) Recent Developments
  37. 8.7 Onconova Therapeutics
  38. 8.7.1 Onconova Therapeutics Company Information
  39. 8.7.2 Onconova Therapeutics Business Overview
  40. 8.7.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Portfolio
  42. 8.7.5 Onconova Therapeutics Recent Developments
  43. 8.8 Nerviano Medical Sciences
  44. 8.8.1 Nerviano Medical Sciences Company Information
  45. 8.8.2 Nerviano Medical Sciences Business Overview
  46. 8.8.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Portfolio
  48. 8.8.5 Nerviano Medical Sciences Recent Developments
  49. 8.9 Jasco Pharmaceuticals
  50. 8.9.1 Jasco Pharmaceuticals Company Information
  51. 8.9.2 Jasco Pharmaceuticals Business Overview
  52. 8.9.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
  54. 8.9.5 Jasco Pharmaceuticals Recent Developments
  55. 8.10 Eternity Bioscience
  56. 8.10.1 Eternity Bioscience Company Information
  57. 8.10.2 Eternity Bioscience Business Overview
  58. 8.10.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Portfolio
  60. 8.10.5 Eternity Bioscience Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 Cyclacel Pharmaceuticals
  68. 8.12.1 Cyclacel Pharmaceuticals Company Information
  69. 8.12.2 Cyclacel Pharmaceuticals Business Overview
  70. 8.12.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
  72. 8.12.5 Cyclacel Pharmaceuticals Recent Developments
  73. 8.13 Celgene Corporation
  74. 8.13.1 Celgene Corporation Company Information
  75. 8.13.2 Celgene Corporation Business Overview
  76. 8.13.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Portfolio
  78. 8.13.5 Celgene Corporation Recent Developments
  79. 8.14 Carna Biosciences
  80. 8.14.1 Carna Biosciences Company Information
  81. 8.14.2 Carna Biosciences Business Overview
  82. 8.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Portfolio
  84. 8.14.5 Carna Biosciences Recent Developments
  85. 8.15 AstraZeneca
  86. 8.15.1 AstraZeneca Company Information
  87. 8.15.2 AstraZeneca Business Overview
  88. 8.15.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca Non-Tyrosine Kinase Inhibitors Product Portfolio
  90. 8.15.5 AstraZeneca Recent Developments
  91. 8.16 Astex Pharmaceuticals
  92. 8.16.1 Astex Pharmaceuticals Company Information
  93. 8.16.2 Astex Pharmaceuticals Business Overview
  94. 8.16.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolio
  96. 8.16.5 Astex Pharmaceuticals Recent Developments
  97. 8.17 Array BioPharma
  98. 8.17.1 Array BioPharma Company Information
  99. 8.17.2 Array BioPharma Business Overview
  100. 8.17.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Array BioPharma Non-Tyrosine Kinase Inhibitors Product Portfolio
  102. 8.17.5 Array BioPharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Non-Tyrosine Kinase Inhibitors Value Chain Analysis
  2. 9.1.1 Non-Tyrosine Kinase Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Non-Tyrosine Kinase Inhibitors Production Mode & Process
  6. 9.2 Non-Tyrosine Kinase Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Non-Tyrosine Kinase Inhibitors Distributors
  9. 9.2.3 Non-Tyrosine Kinase Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst